Catheter Precision reports preliminary 2023 revenue $442K, net loss $72.4M including $61M goodwill impairment

Catheter Precision, Inc.

Q4 2023 revenue ~$129K; full-year revenue ~$442K.
Preliminary net loss: Q4 ~($2.5M), FY ~($72.4M) includes $61M one-time goodwill impairment.
Cash on hand $3.6M; shareholders equity $19.4M as of Dec 31, 2023.
Launched LockeT closure product; enrolled 100+ patients in Phase I study; IRB approved Phase II.
VIVO active in six European countries; IP portfolio expanded to 50 patents worldwide.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Catheter Precision, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $129,000 for the quarter and $442,000 for the year, net income net loss was approximately ($2.5) million for the quarter and ($72.4) million for the year.

Period: fourth quarter and full year ended December 31, 2023
Revenue: $129,000 for the quarter and $442,000 for the year
Net income: net loss was approximately ($2.5) million for the quarter and ($72.4) million for the year
Result: preliminary results

Exact text from the filing

results of the fourth quarter and year ended December 31, 2023, include the following: · Total revenues for the quarter and year ended December 31, 2023, were approximately $129,000 and $442,000, respectively. · Total cash on hand as of December 31, 2023, was approximately $3.6 million. · Total assets as of December 31, 2023, subject to adjustment, was $30.7

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Catheter Precision, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-000467

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.